Compare BlackBerry Limited (BB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BlackBerry Limited vs TG Therapeutics Inc — how do they compare? BlackBerry Limited trades at $8.96 (market cap $5.27B), while TG Therapeutics Inc trades at $50.4 (market cap $7.64B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, BlackBerry Limited nearer its low. Which is the better fit depends on your goals.
| BB | TGTX | |
|---|---|---|
Market Cap | $5.27B | $7.64B |
Sector | Technology | Health |
52-Week High | $12.81 | $59.06 |
52-Week Low | $3.15 | $26.94 |
Enterprise Value | $5.14B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BlackBerry (BB) trades at $8.83, down 1.67% on the day, with a neutral technical outlook despite recent earnings beats. The company shows improving fundamentals with Q1 2026 EPS beating expectations at $0.06 versus $0.05 forecast, and revenue growth accelerating to 26% year-over-year in the latest quarter. Positive cash flow from operations of $16.5 million in 2025 marks a significant turnaround from previous years of negative operational cash flow.
While BlackBerry demonstrates strong momentum in QNX and secure communications segments with raised FY2027 guidance, the stock faces headwinds from premium valuation metrics (P/E 89.8, P/S 9.22) and execution risks in its automotive software transition. The 14.29% buy rating among analysts suggests cautious optimism, with the consensus price target of $10.50 implying 19% upside potential from current levels.
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BlackBerry Limited
BlackBerry Limited provides intelligent security software solutions. The Company offers artificial intelligence and machine learning for cybersecurity, safety, and data privacy solutions, as well as endpoint security and management, encryption, and embedded systems. BlackBerry serves governments and enterprise sectors worldwide.
Read more on BB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
